HIV prevention

For decades, Gilead has been at the forefront of the HIV epidemic, having developed the first pre-exposure prophylaxis (PrEP) medication to prevent HIV infection. Now, with the help of clinical trial volunteers, we continue our quest to develop new effective HIV prevention options for everyone who may need or want PrEP.

Featured trials

STATUSRecruiting

HIV prevention: GS-US-712-7286

Purpose 365: A Phase 3 Study to Evaluate the Safety of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP).

The HIV landscape

Where we stand with HIV infection

31,800

In 2022, there were 31,800 estimated new HIV infections in the US, a 12% decline since 2018.

Source: CDC.gov

1.2M

Approximately 1.2 million people in the US have HIV. About 13 percent of them don’t know they have it.

Source: HIV.gov

1 in 7

Between 2006-2017, 1 in 7 transgender women in the US were living with HIV, with Black and Latina transgender women impacted at significantly higher rates.

Source: Becasen JS et al, 2018

49%

In 2022, almost half (49%) of new HIV infections in the US were in the US South.

Source: CDC.gov

The focus of Gilead

Our commitment to HIV prevention

Learn about PrEP and ongoing studies

PrEP (pre-exposure prophylaxis) is the routine use of prescription medicine before a person is exposed to HIV through sex, to reduce their risk of getting it
Per the CDC, when taken as prescribed, PrEP reduces the risk of getting HIV through sex by 99%, and through injection drug use by at least 74%. However, not everyone who could benefit from PrEP is using PrEP. Many individuals, especially persons of color, face many individual, social, and structural barriers to accessing PrEP and other sexual health services
PrEP medication does not protect against other sexually transmitted infections (STIs), so consistent condom use is important

Learn more

Partnering for inclusion in clinical trials

“Ever since the beginning of the HIV epidemic, we’ve known that the science is better when everyone has a seat at the table,” says Moupali Das, Gilead’s HIV Prevention Clinical Lead. For that reason, Gilead’s PURPOSE clinical trials engage Global Community Advisory Groups (G-CAGs) for their input on the community, cultural considerations, and more. G-CAG members were selected based on their significant contributions to the HIV space in their communities, in advocacy, and experience with clinical development work.

Learn more

Beyond clinical trials

Aiming to reduce HIV among young women and girls

Girls and young women account for 71% of new HIV infections among adolescents in sub-Saharan Africa. Through the DREAMS initiative, which is led by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Gilead provides funding for PrEP with the goal of helping young women stay HIV-free. In its first year, DREAMS reached one million adolescent girls and young women and saw a 25% to 40% reduction in new HIV diagnoses in 65% of DREAMS districts.

Learn more

Igniting change

Gilead supports the work of grassroots organizations that are helping address a collective mission and advance education in the HIV space.

Some key Gilead partnerships and initiatives

Community voices

Meet the people and programs dedicated to improving HIV care

Women living with HIV help redefine long-term treatment success

In Europe, women, particularly those from migrant communities, are disproportionately affected by new HIV cases. Three women are working to change this narrative. Read their stories of turning an HIV diagnosis into a mission of empowerment for other women.

HIV epidemic in the US south

The Gilead COMPASS Initiative^®, is a 10-year, $100+ million commitment to addressing the HIV epidemic in the Southern United States. In its fifth year, COMPASS has worked closely with and provided funding to nearly 400 community-based organizations across 16 states in the U.S South that address health inequities and other barriers to care.

Explore our other HIV research areas

HIV treatment

We're focusing on advancing a pipeline of investigational options to create HIV treatments. Learn more about HIV treatment clinical trials.

HIV in children

An estimated 1.7 million children under the age of 15 live with HIV. Gilead is deeply committed to the discovery and development of urgently needed, age-appropriate treatments for children living with HIV. Learn more about Gilead’s work in Pediatric HIV.